pirtobrutinib,rituximab,venetoclax
eli lilly,roche,abbvie
['mantle,(-dismantle)', 'bruin', 'lymphoma', 'valent ,(-prevalent)', 'loxo', 'valent ,(-prevalent),(-equivalent),(-bivalent)']
updated results &amp; subgroup analysis w/ 2yrs of survival follow-up from the phase 1/2 bruin study, investigating a highly selective, non-covalent (reversible) btki in pts w/ #mantlecelllymphoma previously treated w/ a covalent btki. presented at #eha2023: 
Dedicated to communicating the latest science & innovation from Loxo@Lilly. Tweets intended for US oncology HCPs. See our community guidelines: https://t.co/1q8vAe63mK